1 Oncology Department, Beijing Hospital of the Ministry of Health, Beijing 100038, China ; 2 Oncology Department, Chinese PLA General hospital, Beijing 100853, China.
Chin J Cancer Res. 2015 Apr;27(2):122-7. doi: 10.3978/j.issn.1000-9604.2015.04.01.
It is necessary to establish an effective therapy to improve the survival of patients with advanced cholangiocarcinoma (CCA). Recently, with the development of pathology research in CCA, a lot of special bio-markers such as EGFR, VEGF, HER2, and MEK et al. could be over expression or mutations in CCA patients. According to their changes, combinations of targeted therapy plus chemotherapy are now recognized as effective therapies for advanced CCA. The aim of this paper is to analyze recent promising studies about targeted therapy alone or combination with each other or with chemotherapies.
有必要建立一种有效的疗法来提高晚期胆管癌（CCA）患者的生存率。最近，随着 CCA 病理学研究的发展，许多特殊的生物标志物，如 EGFR、VEGF、HER2 和 MEK 等，在 CCA 患者中可能过度表达或发生突变。根据这些变化，目前已将靶向治疗联合化疗作为晚期 CCA 的有效治疗方法。本文旨在分析近期关于靶向治疗单独或联合应用或与化疗联合应用的有希望的研究。
